Last reviewed · How we verify
NCT04034082
Intermittent Hypoxia Therapy in Cardiac Rehabilitation
NA trial testing Intermittent hypoxia therapy in Cardiovascular Disease in 30 participants. Completed in 30 October 2020.
30 June 2020
Quick facts
| Lead sponsor | Istituti Clinici Scientifici Maugeri SpA |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 12 February 2019 |
| Primary completion | 30 June 2020 |
| Estimated completion | 30 October 2020 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Intermittent hypoxia therapy
- Conventional phase 2 cardiac rehabilitation programme
Conditions studied
- Cardiovascular Disease — all drugs for Cardiovascular Disease →
- Exercise — all drugs for Exercise →
- Hypoxia — all drugs for Hypoxia →
Sponsor
Istituti Clinici Scientifici Maugeri SpA
Who can join
75 and older, any sex, with Cardiovascular Disease or Exercise. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized control pilot study to assess the effect of intermittent hypoxia therapy on functional capacity vs conventional care in old patients with functional impairment admitted to a Phase 2 in-hospital cardiac rehabilitation program.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04034082
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiovascular Disease
Currently open trials in the same condition.
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT07293260 — Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial · Phase 3 · recruiting
- NCT07497932 — Nutritional Effects in Cardiovascular Surgery · NA · recruiting
- NCT06625073 — Randomized Trial of SGLT2i in Heart Transplant Recipients · Phase 4 · recruiting
- NCT06485700 — Peers and Technology for Adherence, Access, Accountability, and Analytics (PT4A) · NA · recruiting
Other Istituti Clinici Scientifici Maugeri SpA trials
Trials by the same sponsor.
- NCT07521436 — Awareness of Risk Factors and Perception of Cardiovascular Risk in Secondary Prevention Among Women and Men · not yet recruiting
- NCT07451977 — Effects of Oxygen Supplementation During the 6-Minute Walk Test in Chronic Respiratory Failure or Exertional Hypoxemia · NA · recruiting
- NCT07448181 — Real-life Ecological Momentary Assessment of Lived Burden in Hereditary AngioEdema · recruiting
- NCT07432204 — Therapeutic Music Listening in Post Stroke Patients. · NA · recruiting
- NCT07399418 — TRIAD - Tracking Risk in Integrated Alzheimer's Diagnostics. · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04034082 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istituti Clinici Scientifici Maugeri SpA
- Last refreshed: 15 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04034082.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing